A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis
This study is being conducted to evaluate the safety, tolerability, and activity of 400 mg of KD025 once-daily (QD) compared to Best Supportive Care(BSC) in male and postmenopausal/surgically sterilized female subjects with IPF.
- Idiopathic Pulmonary Fibrosis
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Accepts Healthy Volunteers
- Adult male and postmenopausal/surgically sterilized female subjects at least 18 years of age (if female, is surgically sterilized [ie, total hysterectomy, or bilateral salpingo-oophorectomy]).
- Able to provide written informed consent before the performance of any study specific procedures.
- IPF diagnosis within 5 years before study entry, proven according to the American Thoracic Society/European Respiratory Society consensus conference criteria, with surgical lung biopsy. In the absence of a surgical lung biopsy, HRCT must be consistent with usual interstitial pneumonitis.
- Resting state SpO2 ≥ 88% with or without supplemental oxygen, FVC % ≥ 50% normal predicted value, and DLCO ≥ 30% normal predicted value at baseline.
- Men with partners of childbearing potential must be willing to use 2 medically acceptable methods of contraception during the trial and for 3 months after the last dose of study drug. Effective birth control includes (a) intrauterine device (IUD) plus 1 barrier method; (b) stable doses of hormonal contraception for at least 3 months (eg, oral, injectable, implant, transdermal) plus 1 barrier method; (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) vasectomy.
- Have adequate bone marrow function:
- ANC > 1500/mm3
- Hemoglobin > 9.0 g/L
- Platelets > 100,000/mm3
- Willing to complete all study measurements and assessments in compliance with the protocol
- Has either received pirfenidone and/or nintedanib or has been offered both treatments (with last dose administered at least 1 month before the expected start of study drug dosing). If either or both pirfenidone and nintedanib treatment has not been given, then documentation that the patient was offered both treatments must be documented.
- Interstitial lung disease caused by conditions other than IPF
- Severe concomitant illness limiting life expectancy (< 1 year)
- Diffusing capacity of the lung for carbon monoxide (DLCO) < 30% predicted
- Residual volume ≥ 120% predicted
- Obstructive lung disease: FEV1/ FVC ratio < 0.70
- Documented sustained improvement of the subject's IPF condition up to 12 months before study entry with or without IPF-specific therapy
- Pulmonary or upper respiratory tract infection within 4 weeks before study entry
- Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements (eg, pulmonary function tests)
- Chronic heart failure with New York Heart Association class III/IV or known left ventricular ejection fraction < 25%
- Moderate to severe hepatic impairment (ie, Child-Pugh Class B or C)
- Estimated creatinine clearance < 30 mL/min
- Aspartate aminotransferase (AST) and/or ALT > 2.0 × upper limit of normal (ULN)
- Hemoglobin < 75% of the lower limit of normal
- Systolic blood pressure < 100 mmHg
- Men whose partner is pregnant or breastfeeding
- Current drug or alcohol dependence
- Chronic treatment with the following drugs (within 4 weeks of study entry and during the study)
- Immunosuppressive or cytotoxic drugs including cyclophosphamide and azathioprine
- Antifibrotic drugs including pirfenidone, nintedanib, D penicillamine, colchicine, tumor necrosis factor α blockers, imatinib and interferon-γ
- Chronic use of N-acetylcysteine prescribed for IPF (> 600 mg/day)
- Oral anticoagulants prescribed for IPF
- Treatment with endothelin receptor antagonists within 4 weeks before study entry
- Systemic treatment within 4 weeks before study entry with cyclosporine A or tacrolimus, everolimus, or sirolimus (calcineurin or mammalian target of rapamycin inhibitors)
- Previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK2 inhibitor
- Planned treatment, or treatment with another investigational drug within 4 weeks before study entry
- Subject is taking a medication that has the potential for QTc prolongation (see Appendix A)
- Subject is taking a drug that is a sensitive substrate of CYP enzymes
- Subject is taking an inhibitor or inducer of CYP3A4
- Subject has consumed an herbal medication (eg, St. John's Wort) or grapefruit/grapefruit juice within 14 days prior to the Week 1, Day 1 visit
- Phase 2
- Study Type
- Intervention Model
- Single Group Assignment
- Primary Purpose
- None (Open Label)
|Two 200mg tablets (400 mg) KD025 once daily (QD). Subjects should take 2 Tablets with their morning meal or within 5 minutes of completing a meal.||
Best Supportive Care
|Best Supportive Care (BSC) which is a treatment/drug determined by each subject's prescribing physician.||
- NCT ID
- Active, not recruiting
- Kadmon Corporation, LLC
Approximately 81 subjects with IPF will be randomly enrolled in a 2:1 ratio (KD025 to BSC) to one of two treatment groups. Subjects randomized to Treatment Group 1 will receive KD025 400 mg QD orally for 24 weeks, with the option for continuation as long as there is no safety signal and clinical progress continues. Subjects randomized to Treatment Group 2 will receive BSC (as deemed appropriate by the investigator). Subjects randomized to BSC will undergo the same procedures and assessments as subjects on KD025.